

# KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2<sup>nd</sup> Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –400002

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1<sup>st</sup> Lane Ambawadi, Ahmedabad,  
Gujarat-380006

Phone: +91-6359637788, Email: [investor.relations@kashyaptele-medicines.com](mailto:investor.relations@kashyaptele-medicines.com),

Website: [www.kashyaptele-medicines.com](http://www.kashyaptele-medicines.com)

---

5<sup>th</sup> August, 2024

To,

**BSE Limited**

Listing Department

Phiroz Jeejeebhoy Tower,

25<sup>th</sup> Floor, Dalal Street,

Mumbai – 400 001

**Scrip Code: 531960**

Dear Sir/ Madam,

**Subject: Submission of “Unaudited Financial Results” and Limited Review Report thereon for the quarter ended 30<sup>th</sup> June, 2024**

With reference to above and pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), find enclosed the Unaudited Financial Results for the quarter ended 30<sup>th</sup> June, 2024, prepared in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Companies (Indian Accounting Standards) Rules, 2015 (IND-AS) along with the Limited Review Report thereon as received from the Statutory Auditors of the Company [M/s. Ravi Karia & Associates., Chartered Accountants, (FRN.:157029W)]. The same has been considered, approved and taken on record by the Board of Directors at their meeting held today i.e. Monday, 5<sup>th</sup> August, 2024.

Further, pursuant to Regulation 46 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the said results will be uploaded on the website of the Company i.e. [www.kashyaptele-medicines.com](http://www.kashyaptele-medicines.com) and will be duly published in the required newspapers within prescribed timeframe.

You are requested to acknowledge and update the same in your records.

Thanks & Regards

**FOR KASHYAP TELE-MEDICINES LIMITED**

**JYOTI SAHU**

**COMPANY SECRETARY & COMPLIANCE OFFICER**

Encl.: “As above”

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
KASHYAP TELE-MEDICINES LIMITED**

1. We have reviewed the accompanying Statement of **Un-audited Financial Results** of **KASHYAP TELE-MEDICINES LIMITED** (the "Company") for the quarter ended **June 30, 2024** (the "Statement") attached herewith being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.





5. The figures for the quarter ended June 30, 2023 as reported in this Statement were reviewed by predecessor auditor who expressed an unmodified conclusion on those financial results dated August 03, 2023.



For, **Ravi Karia & Associates**  
Firm Registration No. 157029W  
Chartered Accountants

**Ravi Karia**  
Partner  
Membership No. 161201  
UDIN: 24161201BKHBCO8187

Place: Ahmedabad  
Date: August 05, 2024

# KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -400002

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006

Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com

Website: www.kashyaptele-medicines.com

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30<sup>th</sup> JUNE, 2024

INR in Lakhs Except EPS


S.No.	Particulars	Quarter Ended			Year Ended
		30-06-2024	31-03-2024	30-06-2023	31-03-2024
		(Unaudited)	(Refer Note 4)	(Unaudited)	(Audited)
I	Revenue from operations	5.90	3.90	4.65	19.20
II	Other Income	-	0.01	-	0.01
III	<b>Total Revenue ( I + II )</b>	<b>5.90</b>	<b>3.91</b>	<b>4.65</b>	<b>19.21</b>
IV	<b>Expenses</b>				
	(a) Cost of materials consumed	-	-	-	-
	(b) Purchases of stock-in-trade	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	(d) Employee benefits expense	3.78	3.92	2.70	12.14
	(e) Finance Cost	-	-	-	-
	(f) Depreciation and amortisation expense	-	-	-	-
	(g) Other expenses	1.78	3.26	1.78	10.03
	<b>Total expenses</b>	<b>5.56</b>	<b>7.18</b>	<b>4.48</b>	<b>22.17</b>
V	<b>Profit / (Loss) Before Tax ( III- IV)</b>	<b>0.34</b>	<b>(3.27)</b>	<b>0.17</b>	<b>(2.96)</b>
VI	<b>Tax Expense :-</b>				
	(a) Current tax	-	(0.08)	0.04	-
	(b) Tax relating to previous year	-	0.04	-	0.04
	<b>Total Tax Expense</b>	<b>-</b>	<b>(0.04)</b>	<b>0.04</b>	<b>0.04</b>
VII	<b>Profit / (Loss) for the period ( V - IV)</b>	<b>0.34</b>	<b>(3.23)</b>	<b>0.13</b>	<b>(3.00)</b>
VIII	<b>Other Comprehensive Income</b>				
	A. Items that will be/will not be reclassified to profit and loss	-	-	-	-
	B. Income tax relating to items that will be / will not be reclassified to profit and loss	-	-	-	-
	<b>Total comprehensive income for the period (VII+VIII)</b>	<b>0.34</b>	<b>(3.23)</b>	<b>0.13</b>	<b>(3.00)</b>
IX	<b>Paid-up Equity Share Capital (Face Value of Rs. 1/- each)</b>	<b>477.22</b>	<b>477.22</b>	<b>477.22</b>	<b>477.22</b>
X	<b>Other Equity excluding revaluation reserves</b>				<b>(413.24)</b>
XXII	<b>Earnings per equity share:</b> Basic and diluted	<b>0.001</b>	<b>(0.007)</b>	<b>0.000</b>	<b>(0.006)</b>

\*Notes Enclosed

Place : Ahmedabad

Date : 05/08/2024

For and on behalf of Board of Directors of  
Kashyap Tele - Medicines Limited



  
Amit Agrawal  
Managing Director  
DIN: 00169061

**Notes to Unaudited Financial Results for the quarter ended 30<sup>th</sup> June, 2024:**

- 1 The above Unaudited Financial Results of the Company for the quarter ended 30th June, 2024 have been reviewed & recommended by the Audit Committee and approved by the Board of Directors in the Meeting held on 05<sup>th</sup> August, 2024. The same have been subjected to Limited Review by the Statutory Auditors.
- 2 The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices & policies to the extent applicable.
- 3 The Company is engaged in single segment i.e. 'Software Sales', therefore has only one reportable segment in accordance with Ind AS 108 'operating segments'.
- 4 The financial results for the quarter ended 31<sup>st</sup> March, 2024 are the balancing figures between the audited figures in respect of the full Financial Year ended on 31<sup>st</sup> March, 2024 and the published year to date figures up to the third quarter ended 31<sup>st</sup> December, 2023.
- 5 A Copy of the aforesaid financial results is also available on the website of BSE Limited ([www.bseindia.com](http://www.bseindia.com)) and on the website of the Company ([www.kashyaptele-medicines.com](http://www.kashyaptele-medicines.com)).
- 6 Figures pertaining to previous year/periods have been re-grouped and re-arranged wherever necessary.

Date : 05/08/2024  
Place : Ahmedabad



For and on behalf of Board of Directors of  
For Kashyap Tele - Medicines Limited



Amit Agrawal  
Managing Director  
DIN: 00169061